Clinical Trials Logo

Clinical Trial Summary

This is a phase IV, multi-center, double-blind, randomized, placebo- controlled study evaluating the effect of alirocumab on SVG atherosclerotic disease burden, as assessed by IVUS at baseline and following 78 weeks of treatment in subjects with at least one intermediate SVG lesion receiving optimal statin therapy. Subjects will be randomized 1:1 into 2 treatment groups: alirocumab 150 mg subcutaneously every 2 weeks or placebo subcutaneously every 2 weeks.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03542110
Study type Interventional
Source Minneapolis Heart Institute Foundation
Contact
Status Terminated
Phase Phase 4
Start date August 4, 2018
Completion date July 31, 2020

See also
  Status Clinical Trial Phase
Completed NCT01121224 - Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty Phase 4